logo
  

INOVIO Presents Data From Combination Trial Of INO-5401 And INO-9012 With Libtayo

INOVIO (INO) said data from the combination trial of INO-5401 and INO-9012 showed that the DNA medicines in combination with PD-1 inhibitor Libtayo (cemiplimab), radiation and temozolomide are tolerable, immunogenic, and may improve median survival for patients with newly diagnosed glioblastoma. The company said the combination of INO-5401 + INO-9012 continues to show a well-tolerated safety profile when given not only with radiation and temozolomide, but also with PD-1 blockade by Libtayo, which is being jointly developed by Regeneron and Sanofi.

Jeffrey Skolnik, INOVIO's senior vice president, clinical development, said, "INO-5401 + INO-9012, with Libtayo and RT/TMZ, generates cancer antigen-specific T cells that may be able to attack GBM and provide a survival advantage."

The company will provide additional data in the coming months, including correlative immunology and tissue data, as well as total study drug exposure and concomitant medication use.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter has rolled out the tipping feature called "Tips" for everyone around the globe using the microblogging site with more payment options to choose from, including cryptocurrencies such as Bitcoin. This is a new way for people to receive and show support on Twitter with money. The feature is currently available on iOS and will be available on Android over the coming weeks. Amazon.com has launched weekly Max-Your-Vax Sweepstakes to encourage their employees to get vaccinated against COVID-19. The sweepstakes began on August 6, 2021 and ends on October 21, 2021, with six draws during the sweepstakes period for 18 prizes worth nearly $2 million, including cash prizes, new vehicle or cash and vacation plus 40 hours of Paid Time Off. Target Corp. announced its plans to hire 100,000 seasonal team members at its stores across the country for this holiday shopping season, though fewer than previous years. With this, the company aims to invest in more flexible scheduling, training, pay and benefits for its existing team members. In a statement, the company said it is also offering around 5 million more hours to its existing staff.
Follow RTT